Eye implant triggers sight improvements in GA at 36-months, pivotal study finds
Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
EADV26: Key late-stage readouts from the conference
In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm…
-
Brainomix’s e-Lung shows progression and treatment response in Phase III trial
Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its AI-powered…
-
Zealand dips on Boehringer-paired obesity drug’s Phase III result
Zealand Pharma’s share price fell by 12% after its partnered obesity hopeful, survodutide, failed to impress in a Phase III…
-
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
Rafael Holdings subsidiary, Cyclo Therapeutics, is forging on with regulatory submissions for its rare metabolic disease therapy despite the drug…
-
Invivyd’s Covid-directed mAb hits Phase III safety goals
Invivyd’s Covid-directed monoclonal antibody (mAb) candidate, VYD2311, has demonstrated strong safety and tolerability in a Phase III study, but shares…
-
Mirum charts positive course for hepatitis delta drug on first Phase III win
Mirum Pharmaceuticals has secured a positive outcome for the first late-stage trial on its chronic hepatitis delta virus (HDV) therapy,…
-
Kodiak’s stock rallies on Phase III wAMD success
Kodiak Sciences’ stock has soared by upwards of 90% after securing a duo of late-stage wins for its ophthalmology candidates,…
-
IMS26: Key readouts rock the multiple myeloma field amid shifting landscape
In recent years, the multiple myeloma space has undergone rapid evolution, with advanced modalities like cell and immunotherapies increasingly moving…
-
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
Acadia Pharmaceuticals has deemed the results of its Phase II study evaluating its Alzheimer’s disease psychosis (ADP) therapy as “Phase…